Friday, 26 April 2019
Latest news
Main » Revance Therapeutics, Inc. (NASDAQ:RVNC) Sees Unusual Volume Mid-Session

Revance Therapeutics, Inc. (NASDAQ:RVNC) Sees Unusual Volume Mid-Session

06 December 2017

Its down 41.94% from 15,500 shares previously.

Among 10 analysts covering Revance Therapeutics (NASDAQ:RVNC), 9 have Buy rating, 0 Sell and 1 Hold. The SI to Revance Therapeutics Incorporated's float is 18.25%. About 3.04M shares traded or 1477.56% up from the average. Revance Therapeutics, Inc. (NASDAQ:RVNC) has risen 20.40% since December 5, 2016 and is uptrending. It has outperformed by 3.70% the S&P500. Lasalle Investment Management Securities Llc sold 164,663 shares as Crown Castle Intl Corp (CCI)'s stock rose 11.44%. Its book value per share for the most recent quarter is $4.69 while its price to book ratio for the same period is 7.41, as for as the company's cash per share for the most recent quarter is $5.08, however its price to cash per share ratio for the same period is 6.84. Crown Castle Intl Corp now has $44.54B valuation. Stock investors purchased 2,062 call options on the stock. About 292,974 shares traded. Crown Castle International Corp. It has underperformed by 16.70% the S&P500. Its up 0.99, from 0.97 in 2017Q1. It worsened, as 46 investors sold CCI shares while 195 reduced holdings. American Registered Advisor, Texas-based fund reported 8,090 shares. The New York-based Ghost Tree Capital Llc has invested 0.49% in the stock. Royal National Bank & Trust Of Canada owns 23,768 shares for 0% of their portfolio. Vanguard Group Inc. now owns 931,623 shares of the biopharmaceutical company's stock worth $24,595,000 after buying an additional 63,505 shares in the last quarter. Whereas 0 of them predict the stock is a hold. The insider now directly owns 141,197 shares worth $4,906,596. Therefore 90% are positive. The stock of Crown Castle International Corp. On Wednesday, August 10 the stock rating was upgraded by KeyBanc Capital Markets to "Overweight". The firm earned "Neutral" rating on Wednesday, June 21 by Seaport Global. The rating was maintained by Cowen & Co with "Buy" on Thursday, October 19. The firm presently has a "buy" rating on the biopharmaceutical company's stock. (NASDAQ:RVNC). Bnp Paribas Arbitrage reported 0% stake. Cubesmart (NYSE:CUBE) was raised too. Its up 0.99, from 0.97 in 2017Q1. Vanguard Group Inc. lifted its stake in shares of Revance Therapeutics by 7.3% in the 2nd quarter. Federated Pa holds 20,000 shares or 0% of its portfolio.

Analysts await Revance Therapeutics, Inc. If the published price targets set by Revance Therapeutics, Inc. analysts have any power to influence the stock's share price, the highest price target set for RVNC is $55. (NASDAQ:RVNC) or 236 shares. Virginia Retirement Et Al reported 136,119 shares. Alps Advsr Inc invested in 27,324 shares. Granite Prns reported 67,961 shares. Ing Groep Nv accumulated 11,909 shares. Parametric Assocs Ltd Liability Com invested in 29,112 shares. (NASDAQ:RVNC) or 5,753 shares. Wells Fargo & Company MN increased its stake in Revance Therapeutics by 19.1% in the third quarter. (NASDAQ:RVNC). Metropolitan Life Insur Ny reported 0% stake. Huntington Fincl Bank holds 0% in Revance Therapeutics, Inc. Cantor Fitzgerald maintained Revance Therapeutics, Inc. (NASDAQ:RVNC) for 13,312 shares.

Fernwood Investment Management LLC Grows Stake in Universal Display Corporation (OLED)
The stock of Universal Display Corporation (NASDAQ:OLED) earned "Hold" rating by Summit Redstone Partners on Monday, July 31. The stock of Universal Display Corporation (NASDAQ:OLED) earned "Hold" rating by Canaccord Genuity on Wednesday, December 9.

Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Sucampo Pharmaceuticals, and ANI Pharmaceuticals Inc. The company has market cap of $804.30 million. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is now in development for the treatment of glabellar lines and cervical dystonia and has the potential to be the first long-acting neurotoxin. It now has negative earnings. The firm also develops WeedBeacon BETA, an interactive app that tracks real-time cannabis usage where physicians can review patient intake and how various cannabinoids have benefited their patient in the medical community, as well as allows users to share in real-time what they're smoking, and connect them to a Web of like-minded cannabis smokers. Mizuho assumed coverage on shares of Revance Therapeutics in a report on Thursday, November 16th.

Agios Pharma has an analyst consensus of Strong Buy, with a price target consensus of $80.17. The firm has "Buy" rating by SunTrust given on Thursday, November 2. Including today's unusual volume, Revance Therapeutics, Inc.'s stock is performing at 25.60% on the year. (NASDAQ:RVNC), with 7 analysts believing it is a strong buy. Zacks downgraded Revance Therapeutics, Inc. RVNC was included in 16 notes of analysts from August 22, 2015. Revance Therapeutics, Inc. (NASDAQ:RVNC) has a 20-Day average volume of 646157. The company was maintained on Thursday, June 8 by Aegis Capital. As per Tuesday, June 14, the company rating was downgraded by Brean Capital.